The estimated Net Worth of Kathleen Sereda Glaub is at least $960 Tysiąc dollars as of 25 September 2018. Kathleen Glaub owns over 14,492 units of Codexis stock worth over $173,448 and over the last 10 years Kathleen sold CDXS stock worth over $786,771.
Kathleen has made over 3 trades of the Codexis stock since 2018, according to the Form 4 filled with the SEC. Most recently Kathleen sold 14,492 units of CDXS stock worth $272,884 on 25 September 2018.
The largest trade Kathleen's ever made was selling 20,094 units of Codexis stock on 19 September 2018 worth over $360,486. On average, Kathleen trades about 4,954 units every 8 days since 2014. As of 25 September 2018 Kathleen still owns at least 63,534 units of Codexis stock.
You can see the complete history of Kathleen Glaub stock trades at the bottom of the page.
Kathleen's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 15 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... oraz John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Codexis executives and other stock owners filed with the SEC include: